SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

Inclusion Criteria: * Meets criteria for 1 of the following groups: * Prospective group, meeting the following criteria: * Evidence of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL) by Pap test * Human papillomavirus (HPV)-16-positive by polymerase chain reaction (PCR) and PGMY09/PGMY11 oligonucleotide primers viral load assay * Medical records-based group, meeting the following criteria: * Medical-record evidence of ASCUS or LSIL by Pap test within the past 6-12 months * Meets 1 of the following criteria: * Liquid-cytology findings of ASCUS or LSIL * Colposcopic evidence of a LSIL by the Reid Index score of 1-5 * Historically persistent HPV-16-infection by PCR and HPV reverse transcription (RT)-PCR * No evidence of high-grade squamous intraepithelial lesions (HSIL) by colposcopy (Reid Index ≥ 6) * Reports no sex partner change since last index Pap screening test * Specimen-based group, meeting the following criteria: * Medical-record evidence of ASCUS or LSIL by Pap test within the past 6-12 months * Liquid-based cytology specimen available * Meets 1 of the following criteria: * Liquid-cytology findings of ASCUS or LSIL * Colposcopic evidence of a LSIL by the Reid Index score of 1-5 * Historically persistent HPV-16-infection by PCR and, where measurable, HPV RT-PCR showing no greater than 3-fold reduction over the index liquid…